Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: further analyses from the LUME-Lung 1 study.
Authors
Heigener, DGottfried, M
Bennouna, J
Bondarenko, I
Douillard, J
Krzakowski, M
Mellemgaard, A
Novello, S
Orlov, S
Summers, Yvonne J
von Pawel, J
Hocke, J
Kaiser, R
Reck, M
Affiliation
Department of Thoracic Oncology, LungenClinic Grosshansdorf, GrosshansdorfIssue Date
2016-10-01
Metadata
Show full item recordCitation
Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: further analyses from the LUME-Lung 1 study. 2016, 27(suppl 6):1276P Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw383.76Additional Links
https://academic.oup.com/annonc/article/2800170/EfficacyType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw383.76